Skip to Accessibility Tools Skip to Content Skip to Footer

Immunotherapy

Your immune system is your body’s defense against abnormal or unhealthy cells. These may be cells infected with a virus. They may be infectious bacterial cells. They could be abnormal cells that are dividing in a rapid and uncontrolled way – and developing into cancer.

It may be possible to treat skin cancer by turning your immune system against the cancer. Several medications are available that:

  • Help your immune system identify cancer cells.
  • Boost your immune system.
  • Create an immune response at the tumor.

Immune system basics

How does the immune system work?

You have two kinds of immune defense: innate immunity and adaptive immunity.1

Innate immune cells are generalists. They recognize patterns that indicate a dangerous (pathogenic) cell. They respond quickly, usually by creating an inflammatory response.1

Adaptive immune cells are specialists.1 The main adaptive immune cells are B-cells and T-cells. Adaptive immune cells recognize particular antigens on invaders. (Antigens are molecules that trigger an immune response.) Once a B- or T-cell recognizes an antigen, it becomes activated. B-cells make antibodies. T-cells kill the infected cells and recruit other immune cells.

T-cells are important targets for medications called immune checkpoint inhibitors. These medications are described in detail below.

How do immune cells communicate?

Immune cells communicate through receptors and ligands.1 You can imagine this like a lock and key. Receptors (the lock) are proteins on the cell surface. They receive chemical signals from outside the cell. These chemical signals (the key) are called “ligands.” When the ligand fits into (binds with) the receptor, it activates the receptor. Activation causes changes within the cell.

Cytokines, which are proteins that act like signaling molecules, are important for immune cell communication. They are ligands for cell surface receptors. Cytokines have a role in cell growth and immune cell activation.

Cytokines can be made in a lab and given in high doses to treat skin cancer. These medications are described in more detail below.

Immune checkpoint inhibitors: targeted immunotherapy

What are immune checkpoint inhibitors?

Immune checkpoint inhibitors are medications that block specific proteins on T-cells or on cancer cells (Figure 1).

The surface of T-cells has receptors that act like brakes. Two important brakes are called PD-1 (“programmed death receptor-1”) and CTLA-4 (“cytotoxic T-lymphocyte-associated protein 4”). These brakes exist to keep the immune response in check. Some cancer cells evolve to engage these brakes. By engaging the brakes on T-cells, cancer cells escape your immune defenses. For example, some cancer cells have a protein called PD-L1 (“programmed death ligand-1”). When PD-L1 binds to PD-1, it acts like an “off switch” for the T-cell. This makes the T-cell ignore the cancer cell.

Immune checkpoint inhibitors block this interaction between T-cells and cancer cells, allowing the immune system to function against the cancer. Keytruda® (pembrolizumab) and Opdivo® (nivolumab), and Libtayo (cemiplimab-rwlc) block the PD-1 receptor on T-cells. Bavencio® (avelumab) blocks the PD-L1 protein on the cancer cell. Yervoy® (ipilimumab) blocks the CTLA-4 receptor.

Figure 1. How Checkpoint Inhibitors Work

A tumor specific T-cell and tumor or antigen-presenting cell communicating

T-cells recognize antigens on tumor cells. However, a second signal is needed in order to recruit other immune cells and kill the cancerous cell. The second signal comes from a “checkpoint” receptor, such as PD-1 or CTLA-4. These receptors are brakes that exist to keep the immune response in check. Some cancer cells evolve ways to engage these brakes and escape your immune defenses. Immunotherapies block this interaction. They enable T-cells to recognize and destroy cancer cells.

What do immune checkpoint inhibitors treat?

Keytruda, Opdivo, and Yervoy treat advanced melanoma. Bavencio is approved to treat Merkel cell carcinoma. Libtayo (cemiplimab-rwlc) is approved for metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC in patients who are not eligible for surgery or radiation to cure their CSCC.

How are targeted immunotherapies given?

All currently available targeted immunotherapies are taken intravenously (in the vein). Your doctor will typically give you the medication every 2 to 4 weeks, depending on the medication. One exception is adjuvant Yervoy, which may eventually be given every 12 weeks. Adjuvant therapy is an additional cancer treatment that is given after the primary (main) treatment. Adjuvant therapy can help lower the risk that the cancer comes back.

What are side effects of targeted immunotherapies?

These medications change how your immune system works. They may cause your immune system to attack normal (healthy) organs and tissue. Rare but serious problems may affect your:

  • Lungs
  • Intestines
  • Liver and kidneys
  • Hormone glands (thyroid, pituitary, adrenal, pancreas)
  • Eyes
  • Muscles and joints

Common side effects of these therapies include:

  • Fatigue
  • Gastrointestinal problems
  • Decreased appetite
  • Joint or muscle pain
  • Rash or itchy skin
  • Cough, shortness of breath
  • Fever

There are additional side effects for each medication. Read the Medication Guide that comes in the package before starting immunotherapy.

Cytokines: general immune boosters

What do cytokines treat?

Whereas targeted immunotherapies act on specific proteins, cytokines are general immune system boosters. They rally your immune system’s defenses to fight cancer cells.

Two cytokines used to treat skin cancer are:

  • Interleukin-2
  • Interferon, which comes in two forms: interferon-alfa and peginterferon

Interleukin-2 tells your body to make more T-cells and Natural Killer cells.2,3 Interferon boosts your immune system by:4,5

  • Activating white blood cells called macrophages and Natural Killer cells.
  • Making T-cells better at killing cancer cells.
  • Potentially preventing cells from growing and dividing.
  • Promoting cancer cell death.

Cytokines can be used as a primary treatment or adjuvant treatment for melanoma or Kaposi sarcoma.6 Cytokines may be used alone or in combination with other medications.

Intralesional immunotherapy

What is an oncolytic virus and how does it work?

Talimogene laherparepvec is a type of medication called an “oncolytic virus.” It shrinks melanoma tumors in the skin and lymph nodes.

The exact way that talimogene laherparepvec works is unknown.7 It is thought to work by:

  • Killing tumor cells directly by causing them to burst open.
  • Creating an immune response. This response involves adaptive immune cells that learn to recognize tumor antigens. It also involves a general immune response leading to production of more white blood cells.

What other intralesional therapies are used to treat melanoma?

The Bacillus Calmette-Guerin (BCG) vaccine has been used to treat stage III or recurrent melanoma for four decades.8 Its use has become less common now that new immunotherapies are available.

This vaccine is made from a strain of bacteria called Mycobacterium bovis. The bacteria are introduced to the body and immune cells travel to the site to fight them.9,10 In the process of destroying the bacteria, the immune cells also destroy nearby abnormal cancer cells.9

Immunotherapy combinations

Can immunotherapies be used together?

It may be possible to combine immunotherapies and target the cancer in two different ways at the same time. For example, Opdivo and Yervoy work on different receptors. For example, Opdivo and Yervoy work on different receptors and may potentially be used together to treat certain forms of melanoma.

Researchers are studying whether cytokines and targeted immunotherapies can be used together.13 The idea is that targeted therapy releases the brakes and cytokines provide more immune system power. Other early studies are being done on Yervoy with talimogene laherparepvec.14 Although the results were promising, more studies are needed know if these combinations are safe and effective.

Written by: Sarah O'Brien | Last reviewed: June 2019.
  1. National Institute of Allergy and Infectious Diseases. Overview of the immune system. Accessed April 14, 2017 at: https://www.niaid.nih.gov/research/immune-system-overview.
  2. Proleukin® [prescribing information]. San Diego, CA: Prometheus Laboratories; January 2015.
  3. Amaria RN, Reuben A, Cooper ZA, Wargo JA. Update on use of aldesleukin for treatment of high-risk metastatic melanoma. Immunotargets Ther. 2015;4:79-89.
  4. Intron A® [prescribing information]. Whitehouse Station, NJ: Schering Corporation; May 2015.
  5. National Cancer Institute. Biological therapies for cancer. Accessed April 13, 2017 at: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/bio-therapies-fact-sheet#q4
  6. NCCN Clinical Practice Guidelines in Oncology. Melanoma. Version 1.2017. Published November 10, 2016. https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf
  7. Imlygic® [prescribing information]. Thousand Oaks, CA: Amgen Inc; March 2017.
  8. Cohen MH, Jessup JM, Felix EL, et al. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer. 1978;41:2456-2463.
  9. American Cancer Society. Intravesical therapy for bladder cancer. Accessed April 17, 2017 at: https://www.cancer.org/cancer/bladder-cancer/treating/intravesical-therapy.html
  10. Sloot S, Rashid OM, Sarnaik AA, Zager JS. Developments in intralesional therapy for metastatic melanoma. Cancer Control. 2016;23:12-20.
  11. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.
  12. Opdivo® [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; February 2017.
  13. Zarour HM, Tawbi H, Tarhini AA, et al. Study of anti-PD-1 antibody pembrolizumab and pegylated-interferon alfa-2b (Peg-IFN) for advanced melanoma. J Clin Oncol. 2015;33:(suppl; abstr e20018).
  14. Puzanov I, Milhem MM, Minor D, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34:2619-2626.